Why Your Shampoo Looks Different in Paris Than in Peoria

The European Union and the United States run fundamentally different systems for deciding what belongs in a bottle of shampoo. Regulation (EC) No 1223/2009, which governs cosmetics across the EU's 27 member states, operates through annexes: Annex II lists substances prohibited outright, Annex III lists substances permitted only under specific restrictions, and Annex IV governs colorants with precise conditions for each. The United States, by contrast, lacks any comparable comprehensive annex system for cosmetic ingredients. Its closest parallel is the FDA's "Regulatory Status of Color Additives" database, a narrow authorization framework that leaves most other cosmetic chemistry to manufacturer discretion. One concrete result: Disodium EDTA-copper, listed in FDA records under §73.2120 as permitted specifically for coloring shampoos, has no automatic path to European shelves under the EU's colorant annexes.

Annexes Versus Authorizations: How the Two Systems Diverge

The EU regulation draws a sharp line between prohibition and restriction. Article 14 states that cosmetic products shall not contain substances listed in Annex II, full stop, subject only to explicit exceptions elsewhere in the text. Article 15 then establishes Annex III for substances that may appear, but only when manufacturers respect concentration limits, product-type restrictions, or labeling requirements spelled out in the annex entry itself. Hair-coloring products face additional constraints: they may contain only colorants listed in Annex IV and only within the conditions laid down there. This creates a default-deny posture for color chemistry in Europe.

The FDA's color additive system works differently. The agency maintains a database and summary tables showing which color additives are permitted for cosmetics, which are restricted to external application, which require certification batches, and which are barred entirely. Disodium EDTA-copper appears in the FDA's "Summary of Color Additives for Use in the United States" with a specific cosmetic use: coloring shampoos. The database does not replicate the EU's annex structure. For non-color ingredients, no FDA annex equivalent exists; the agency can act against adulterated or misbranded cosmetics post-market, but it does not maintain a pre-market positive or negative list comparable to Annexes II, III, and IV.

When the Same Shampoo Carries Different Chemistry

A manufacturer selling on both sides of the Atlantic faces a practical translation problem. A colorant that satisfies FDA authorization for shampoo may fall outside Annex IV's European conditions, or appear there only with restrictions the formula cannot meet. The FDA's labeling guide adds another layer: color additives added during manufacture for color matching may be declared on the label of each batch or lot even if not present in every unit. This batch-level declaration possibility has no direct EU parallel; European cosmetic labeling operates under the Information and Labelling chapter of Regulation 1223/2009, with ingredient lists required to reflect the actual composition placed on the market.

The structural mismatch means a formulation optimized for FDA color-additive compliance may require complete reformulation for EU Annex IV compliance. A shampoo colored with Disodium EDTA-copper in the US, where the FDA explicitly permits this use, would need a different colorant strategy for Europe, where the substance's status depends on whether and under what conditions it appears in Annex IV. The EU does not automatically recognize FDA authorizations; reciprocity is not built into either regulatory framework.

The Ingredients Readers Actually Encounter

Secondary reporting has documented several categories where the Atlantic gap is visible to consumers. D&C Violet 2, Basic Blue 7 and Basic Blue 9 stay in use in US cosmetics while they are banned in Europe. Parabens, restricted in the EU, continue to appear in US skin and hair products. Several phthalates face EU cosmetics bans, while US restrictions apply only to children's toys and childcare products under separate consumer product safety rules, not to cosmetics themselves.

These examples share a pattern: the EU has moved substances to Annex II or imposed Annex III restrictions, while the US either never restricted them for cosmetics or regulates them under entirely different statutory authorities. The EU's European Chemicals Agency maintains a public cosmetics prohibited-substances list, updated through delegated acts; the FDA has no comparable public-facing consolidated list of banned cosmetic ingredients beyond its color additive tables.

Reading "Banned" Correctly

A listing in Annex II or Annex III is a regulatory classification, not a medical verdict on every conceivable exposure. The EU framework deliberately distinguishes prohibition from restriction: Annex III substances are not "dangerous" in all contexts but are deemed to require controlled use—concentration caps, specific product categories, warning labels, or professional-use-only distribution. The 2026 Omnibus Act VIII update notes that new substances join the restricted or prohibited lists based on risk assessments that consider exposure patterns, not intrinsic hazard alone.

The US absence of comparable annexes does not mean substances are "proven safe"; it means the FDA's legal authority to prohibit cosmetic ingredients pre-market is constrained by the Federal Food, Drug, and Cosmetic Act's structure, which emphasizes post-market enforcement against adulteration. The two systems make different bets on regulatory timing and evidentiary thresholds.

What Manufacturers Actually Do

Cosmetic companies operating in both markets typically maintain parallel formulations. For colorants, this means selecting Annex IV-listed options for EU production even when FDA-authorized alternatives would perform identically. The reformulation burden falls heaviest on products where color is functional—shampoos marketed for gray coverage, toning, or aesthetic tint—since these rely on chemistry that sits at the intersection of the FDA's narrow authorization and the EU's annex conditions.

Label differences follow. An EU shampoo lists colorants by their CI (Colour Index) numbers as Annex IV requires. A US counterpart may list the same functional result achieved through FDA-authorized chemistry with different nomenclature, or achieve similar visual effects through means the EU would classify and restrict differently. The consumer sees different ingredient lists not because one product is adulterated, but because each list reflects compliance with a different regulatory architecture.

The divergence will widen before it narrows. Omnibus Act VIII adds 18 substances to restricted or prohibited status from May 2026. The FDA has announced no comparable expansion of pre-market ingredient authority. Shoppers comparing labels across borders are not decoding safety; they are reading the output of two different machines for turning chemical risk assessment into market permission.